Go Pro

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

Palvella Therapeutics logo
$149.15 -1.18 (-0.78%)
As of 02:53 PM Eastern

Palvella Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
0
Buy
14

Based on 15 Wall Street analysts who have issued ratings for Palvella Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 1 has given a sell rating, 12 have given a buy rating, and 2 have given a strong buy rating for PVLA.

Consensus Price Target

$209.14
40.22% Upside
According to the 15 analysts' twelve-month price targets for Palvella Therapeutics, the average price target is $209.14. The highest price target for PVLA is $270.00, while the lowest price target for PVLA is $133.00. The average price target represents a forecasted upside of 40.22% from the current price of $149.15.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PVLA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Palvella Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PVLA Analyst Ratings Over Time

TypeCurrent Forecast
8/28/25 to 8/28/26
1 Month Ago
7/29/25 to 7/29/26
3 Months Ago
5/30/25 to 5/30/26
1 Year Ago
8/28/24 to 8/28/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
10 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$209.14$199.53$199.53$58.50
Forecasted Upside40.22% Upside39.93% Upside68.44% Upside14.04% Upside
Consensus RatingBuyBuyModerate BuyBuy

PVLA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PVLA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Palvella Therapeutics Stock vs. The Competition

TypePalvella TherapeuticsHealthcare CompaniesBroader Market
Consensus Rating Score
3.00
2.30
2.53
Consensus RatingBuyHoldModerate Buy
Predicted Upside38.09% Upside816.06% Upside12.80% Upside
News Sentiment Rating
Positive News

See Recent PVLA News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/5/2026
Truist Financial Corporation logo
Truist Financial
3 of 5 stars
 Set Target$207.00+35.59%
8/5/2026 Set Target$232.00+49.26%
7/28/2026
Chardan Capital logo
Chardan Capital
5 of 5 stars
Geulah Livshits
Geulah Livshits
5 of 5 stars
UpgradeStrong-Buy
7/22/2026Reiterated RatingBuy$270.00+87.58%
6/29/2026 Reiterated RatingSell (D-)
5/21/2026Reiterated RatingOverweight$220.00+90.14%
2/25/2026Boost TargetOutperform$205.00 ➝ $250.00+103.98%
2/25/2026Boost TargetBuy$192.00 ➝ $215.00+78.56%
2/24/2026Set Target$250.00+108.96%
2/2/2026Reiterated RatingBuy
Why major institutions are piling into this digital asset now (Ad)

BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel

Get the name, the ticker, and exactly how to buy it
12/16/2025Reiterated RatingStrong-Buy$193.00+116.90%
12/15/2025Reiterated RatingBuy$143.00+62.70%
12/15/2025Reiterated RatingOutperform$200.00+124.67%
12/4/2025Initiated CoverageBuy$175.00+90.40%
11/6/2025Boost TargetOverweight$120.00 ➝ $200.00+151.54%
8/4/2025Initiated CoverageOutperform$90.00+146.24%
3/25/2025Initiated CoverageBuy$45.00+61.46%
3/7/2025Initiated CoverageSector Outperform$50.00+108.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:18 PM ET.


PVLA Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Palvella Therapeutics is $209.14, with a high forecast of $270.00 and a low forecast of $133.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palvella Therapeutics in the last twelve months. There is currently 1 sell rating, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PVLA shares.

According to analysts, Palvella Therapeutics's stock has a predicted upside of 40.22% based on their 12-month stock forecasts.

Over the previous 90 days, Palvella Therapeutics's stock had 1 upgrade by analysts.

Palvella Therapeutics has been rated by research analysts at Canaccord Genuity Group, Chardan Capital, HC Wainwright, Truist Financial, and Weiss Ratings in the past 90 days.

Analysts like Palvella Therapeutics more than other "healthcare" companies. The consensus rating for Palvella Therapeutics is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how PVLA compares to other companies.


MarketBeat monitors more than a dozen sources for Palvella Therapeutics analyst ratings, with the most recent rating issued on 8/5/2026.
From Our Partners